Literature DB >> 23644923

Squamous intraepithelial lesions in HIV-infected women: prevalence, incidence, progression and regression.

Regis Kreitchmann1, Halim Bajotto, Daila Alena Raenck da Silva, Sandra Costa Fuchs.   

Abstract

PURPOSE: To evaluate the impact of HIV immune depletion, highly active antiretroviral therapy (HAART) and patient characteristics on the occurrence of cervical squamous intraepithelial lesions (SIL).
METHODS: A total of 898 HIV-positive women were evaluated at the time of their first Pap smear and 388 of them received additional Pap smears during follow-up in a cohort study. The patients were enrolled from July 1997 to April 2007. Prevalence and incidence of SIL in Pap smears were studied. Progression and regression were evaluated in follow-up of patients presenting low-grade SIL.
RESULTS: Pap smear results at baseline were: 741 normal (82.5 %), 56 atypical squamous cells of indeterminate significance (ASCUS) (6.2 %), 78 low-grade SIL (8.7 %), 22 high-grade SIL (2.4 %), and 1 invasive cervical cancer (0.1 %). SIL cumulative incidence rate was 9.7 %. Progression and regression occurred in 15.9 and 62 %, respectively. Multivariate analysis of CD4 counts ≤ 200 cells/mm(3) (aHR = 2.1; 95 % CI 1.3-3.5; P = 0.004) and age less than 30 years (aHR = 3.2; 95 % CI 1.5-6.8; P = 0.01) or less than 40 years old (aHR = 2.6; 95 % CI 1.2-5.7; P = 0.01) were significantly associated with SIL prevalence. CD4 counts ≤ 200 cells/mm(3) (aHR = 3.0; 95 % CI 1.2-7.2; P = 0.01) and higher viral load counts (for each log increase) were associated with SIL incidence (aHR = 1.4; 95 % CI 1-1.9; P = 0.048).
CONCLUSIONS: Prevalence and incidence of SIL in HIV-positive women were associated with severity of HIV disease. Interventions to increase access to Pap smears and further diagnostic tests should be implemented and targeted to HIV-positive women.

Entities:  

Mesh:

Year:  2013        PMID: 23644923     DOI: 10.1007/s00404-013-2871-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

1.  TGFβ receptor 1: an immune susceptibility gene in HPV-associated cancer.

Authors:  Chaya Levovitz; Dan Chen; Emma Ivansson; Ulf Gyllensten; John P Finnigan; Sara Alshawish; Weijia Zhang; Eric E Schadt; Marshal R Posner; Eric M Genden; Paolo Boffetta; Andrew G Sikora
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

2.  Comparison of Abnormal Cervical Cytology from HIV Positive Women, Female Sex Workers and General Population.

Authors:  Homeira Vafaei; Nasrin Asadi; Leila Foroughinia; Alireza Salehi; Safieh Kuhnavard; Mojgan Akbarzadeh; Hamid Reza Ravanbod; Ferdos Mohamadalian; Maryam Kasraeian
Journal:  Int J Community Based Nurs Midwifery       Date:  2015-04

3.  Risk factors for cervical HPV infection and genotypes distribution in HIV-infected South Brazilian women.

Authors:  Sheila C Rocha-Brischiliari; Fabrícia Gimenes; André L P de Abreu; Mary M T Irie; Raquel P Souza; Rosangela G Santana; Angela A F Gravena; Maria D de B Carvalho; Marcia E L Consolaro; Sandra M Pelloso
Journal:  Infect Agent Cancer       Date:  2014-02-11       Impact factor: 2.965

Review 4.  Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis.

Authors:  Helen Kelly; Helen A Weiss; Yolanda Benavente; Silvia de Sanjose; Philippe Mayaud
Journal:  Lancet HIV       Date:  2017-10-26       Impact factor: 12.767

5.  Hybrid capture as a tool for cervical lesions screening in HIV-infected women: insights from a Brazilian cohort.

Authors:  Emilia Moreira Jalil; Paula M Luz; Marcel Quintana; Ruth Khalili Friedman; Rosa M Domingues S Madeira; Angela Cristina Andrade; Janice Chicarino; Ronaldo Ismerio Moreira; Monica Derrico; José Eduardo Levi; Fabio Russomano; Valdilea Gonçalves Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2017-12-06       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.